UA74600C2 - Кристаллическая соль металла и глюкозаминсульфата и способ получения (варианты) - Google Patents
Кристаллическая соль металла и глюкозаминсульфата и способ получения (варианты) Download PDFInfo
- Publication number
- UA74600C2 UA74600C2 UA2003054898A UA2003054898A UA74600C2 UA 74600 C2 UA74600 C2 UA 74600C2 UA 2003054898 A UA2003054898 A UA 2003054898A UA 2003054898 A UA2003054898 A UA 2003054898A UA 74600 C2 UA74600 C2 UA 74600C2
- Authority
- UA
- Ukraine
- Prior art keywords
- formula
- metal
- differs
- glucosamine
- water
- Prior art date
Links
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 55
- 239000002184 metal Substances 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 36
- 150000003839 salts Chemical class 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title abstract description 13
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 title abstract 5
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 30
- 239000011734 sodium Substances 0.000 claims abstract description 30
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 28
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 24
- 239000011591 potassium Substances 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 230000002917 arthritic effect Effects 0.000 claims abstract description 14
- 230000001154 acute effect Effects 0.000 claims abstract description 7
- 230000001684 chronic effect Effects 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 5
- 230000001575 pathological effect Effects 0.000 claims abstract description 5
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims description 53
- 229960002849 glucosamine sulfate Drugs 0.000 claims description 45
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 19
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- 239000003125 aqueous solvent Substances 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract description 5
- 230000000552 rheumatic effect Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 22
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical class N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 12
- 229960002442 glucosamine Drugs 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 10
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- 201000008482 osteoarthritis Diseases 0.000 description 7
- 159000000000 sodium salts Chemical class 0.000 description 7
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000002682 Hyperkalemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- -1 salt glucosamine sulfate Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- CAOFVLJHCHGTGE-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydroiodide Chemical compound I.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CAOFVLJHCHGTGE-BTVCFUMJSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Данное изобретение относится к новым кристаллическим солям металла и глюкозаминсульфата и применяется при лечении острых и хронических форм ревматических и артритных заболеваний, а также других патологических состояний, вызванных метаболическими нарушениями в тканях костей и суставов. В частности, в данном изобретении описаны новые соли глюкозаминсульфата с низким содержанием металла, причем металлом может быть как натрий, так и калий. Данное изобретение также относится к процессам получения солей глюкозаминсульфата с низким содержанием металла, как в растворе, так и без растворителя. Описаны также фармацевтические композиции, в состав которых входят эти соли глюкозаминсульфата.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1088MU2000 | 2000-12-01 | ||
| PCT/IN2001/000211 WO2002043653A2 (en) | 2000-12-01 | 2001-12-03 | Crystalline glucosamine sulphate metal salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA74600C2 true UA74600C2 (ru) | 2006-01-16 |
Family
ID=37454374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2003054898A UA74600C2 (ru) | 2000-12-01 | 2001-03-12 | Кристаллическая соль металла и глюкозаминсульфата и способ получения (варианты) |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA74600C2 (ru) |
-
2001
- 2001-03-12 UA UA2003054898A patent/UA74600C2/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101454004B (zh) | 作为mek抑制剂的吡啶酮磺酰胺类和吡啶酮硫酰胺类 | |
| ES2223615T3 (es) | Procedimiento para la preparacion de atorvastatina amorfa. | |
| ES2605579T3 (es) | Sal de cinc de rosuvastatina | |
| US6812223B2 (en) | Crystalline glucosamine sulfate metal salts and processes for preparing the same | |
| EP0941999A2 (en) | Preparation of azithromycin dihydrate | |
| AU2002217416A1 (en) | Crystalline glucosamine sulphate metal salts | |
| JP2023509242A (ja) | 新規なエンパグリフロジンの共結晶 | |
| EP1781602A1 (en) | 4-sulfonyl-substituted benzoylalanine derivatives useful as kynurenine-aminotransferase inhibitors | |
| UA74600C2 (ru) | Кристаллическая соль металла и глюкозаминсульфата и способ получения (варианты) | |
| JP4177471B2 (ja) | 混合グルコサミン塩の製造法 | |
| WO2002090363A1 (en) | ANHYDROUS CRYSTAL OF ss-LACTAM COMPOUND AND METHOD FOR PREPARATION THEREOF | |
| CS209855B2 (en) | Method of making the new aminoacids derivatives | |
| CN1064681C (zh) | 杂环化合物 | |
| EP0420224B1 (en) | Antihepatopathic composition | |
| ZA200304185B (en) | Crystalline glucosamine sulphate metal salts | |
| LT5148B (lt) | Kristalinės gliukozamino sulfato metalų druskos ir jų gavimo būdas | |
| US3862061A (en) | Imidazole derivatives | |
| WO2016159833A1 (ru) | Лекарственное средство с гепатопротекторной активностью | |
| EP0368758A2 (fr) | Le cystéate de zinc, sa préparation et ses applications pharmaceutiques et cosmétologiques | |
| ITMI930749A1 (it) | Derivato dell'acido iodesossicolico | |
| JPH1045592A (ja) | 糖尿病合併症治療剤 | |
| IT8922055A1 (it) | Esteri del cefamandolo nafato, procedimento per la loro preparazione e relative composizioni farmaceutiche. |